Breaking News from ADA 2019
This page was last updated at 3:30 pm PT on June 11, 2019.
Editor’s Note: This article will be updated regularly with breaking news and announcements during the course of the ADA Scientific Sessions Conference. Check back often! Follow along on Twitter at #ADA2019
Tuesday, June 11
- Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial. Demonstrating non-inferiority of major adverse cardiovascular events (MACE) with the drug compared to placebo was a primary endpoint. The results are based on 137 first MACE and a median follow-up time of 16 months.
Monday, June 10
- Findings from the EMPA-REG OUTCOME® trial found that Jardiance® (empagliflozin) reduces cardiovascular and renal risk in adults with type 2 diabetes and known cardiovascular disease, who also have a form of chronic kidney disease without high levels of protein present in the urine. More than 500 million people around the world have kidney disease, up to 40 percent of whom also have diabetes.
Sunday, June 9
- Sub-analysis of data from DECLARE-TIMI 58 trial shows a 47 percent reduction of composite kidney function decline, end-stage renal disease or death from the use of dapagliflozin.
- The results for the REWIND trial showed dulaglutide reduced cardiovascular events and kidney problems in older and middle-aged adults with type 2 diabetes. The five-year study evaluated more than 9,900 people over the globe—6 continents and 24 countries—demonstrated a 12 percent reduction in CV events like heart attack and stroke in both men and women, with or without previous cardiovascular disease. The drug also reduced the development of kidney disease by 15 percent.
- Two RISE Clinical Trials measuring Beta-cell function in adults with impaired glucose tolerance or newly diagnosed type 2 diabetes (T2D) showed improved β-cell function during active treatment but unfortunately did not produce any prolonged benefits after treatment had ended. The data suggests continued intervention may be required to alter progressive β-cell dysfunction.
- According to two pivotal phase 3 studies, Eli Lilly and Company’s ultra rapid lispro (URLi) provided non-inferior A1C reductions compared to Humalog® (insulin lispro) at 26 weeks in people with type 1 and type 2 diabetes. The data from these studies also showed significant post-meal blood glucose (BG) reductions—one hour and two hours after a test meal compared to Humalog.
Saturday, June 8
- One Drop launched eight-hour blood glucose forecasts, expanding their AI-powered Predictive Insights to cater to the type 2 diabetes audience. This makes One Drop the first and only provider of BG forecasts for people with T2D.
- TODAY2 study data shows accelerated rates of severe complications such as renal, cardiac, eye, nerve and pregnancy issues in young adults with youth-onset type 2 diabetes. The research points to a huge need for more aggressive T2D management to minimize or even prevent the development of serious complications.
- Results of the international PREVIEW intervention study found a low, similar rate of progression to type 2 diabetes (T2D) among people with prediabetes who had initially lost weight on a low-calorie diet. The results show a cumulative three-year incidence rate of #T2D dropping to 4 percent with significant weight loss and education for patients with prediabetes.
- New, evidence-based recommendations for time-in-range targets have been determined by an international panel of diabetes experts striving for accurate parameters for continuous glucose monitor (CGM) blood glucose level goals in both research and clinical settings. While the panel explains that CGM-based targets must be personalized to meet the needs of each individual, there is a general consensus on recommendations based on data from large pre-CGM clinical trials, CGM randomized controlled trials and expert opinion.
- According to the DiRECT study, insulin-producing pancreatic beta cells in people with type 2 are not irreversibly lost during the early stages of diabetes and can be restored through the removal of excess fat in the cells.
- Oral semaglutide showed superior reductions in blood sugar vs Jardiance® and non-inferior blood sugar reductions vs Victoza® in adults with type 2 diabetes at 26 weeks. In PIONEER 2, oral semaglutide showed a superior A1c reduction of 1.3 percent compared to a 0.9 percent reduction with empagliflozin. In PIONEER 4, oral semaglutide showed a 1.2 percent A1c reduction vs. 1.1 percent with Victoza.
- Abbott announced new data showing the use of its FreeStyle Libre system significantly reduced hemoglobin A1c (HbA1c) levels for people living with type 2 diabetes on intensive insulin therapy. The results were analyzed from retrospective, real-world data in three countries across Europe and showed a nearly 1 percent drop in A1c from 8.9 percent to 8.0 percent.
Friday, June 7
- New research presented at Scientific Sessions today shows that vitamin D supplements do not significantly reduce risk of developing type 2 diabetes among those who are vitamin-D sufficient and at risk for developing the condition. The D2d Study was conducted by the Diabetes and Lipid Center at Tufts Medical Center.
Thursday, June 6
- Abbott announced that the FreeStyle LibreLink app for Android users is now available in the U.S. The app was previously only available on iOS.
- Xeris Pharmaceuticals announced a PDUFA date extension for the Gvoke™ HypoPen. Instead of June 10, the Gvoke™ will receive an FDA decision by September 10, 2019.
- Senseonics announced that the Eversense CGM system received FDA approval for a non-adjunctive indication. Patients may have already been relying on Eversense for dosing, but this FDA approval marks a step towards one day using Eversense in a closed-loop system.
- Ahead of the official start of ADA 2019, the American Diabetes Association made important changes to its 2019 Standards of Care for diabetic nephropathy based on the results of the CREDENCE (Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy) trial. Results showed the risk of end-stage renal disease, doubling of serum creatinine, and death from renal causes lowered by 34 percent after treatment with SGL2 inhibitor canagliflozin. The ADA’s updates for clinicians include changes to the frequency of assessing urinary albumin and estimated glomerular filtration rate; the time at which T2D patients with nephropathy should be treated with an SGLT2 inhibitor; the use of GLP-1s to reduce the risk of cardiovascular events, and removal of previous recommendations for microvascular complications and foot care.
Click here for complete coverage of ADA 2019 from Beyond Type 2.